210
https://doi.org/10.1158/1055-9965.
epi-07-2734- Miller CT, Aggarwal S, Lin TK, Dagenais SL,
Contreras JI, Orringer MB, Glover TW, Beer
DG, Lin L (2003) Amplification and overex-
pression of the dual-specificity tyrosine-(Y)-
phosphorylation regulated kinase 2 (DYRK2)
gene in esophageal and lung adenocarcinomas.
Cancer Res 63:4136–4143 - Hasina R, Mollberg N, Kawada I, Mutreja K,
Kanade G, Yala S, Surati M, Liu R, Li X, Zhou
Y, Ferguson BD, Nallasura V, Cohen KS,
Hyjek E, Mueller J, Kanteti R, El Hashani E,
Kane D, Shimada Y, Lingen MW, Husain AN,
Posner MC, Waxman I, Villaflor VM, Ferguson
MK, Varticovski L, Vokes EE, Gill P, Salgia R
(2013) Critical role for the receptor tyrosine
kinase EPHB4 in esophageal cancers. Cancer
Res 73:184–194. https://doi.org/10.1158/
0008-5472.can-12-0915 - Hjortland GO, Meza-Zepeda LA, Beiske K,
Ree AH, Tveito S, Hoifodt H, Bohler PJ, Hole
KH, Myklebost O, Fodstad O, Smeland S,
Hovig E (2011) Genome wide single cell anal-
ysis of chemotherapy resistant metastatic cells
in a case of gastroesophageal adenocarcinoma.
BMC Cancer 11:455. https://doi.
org/10.1186/1471-2407-11-455 - Tokunaga R, Imamura Y, Nakamura K,
Ishimoto T, Nakagawa S, Miyake K, Nakaji Y,
Tsuda Y, Iwatsuki M, Baba Y, Sakamoto Y,
Miyamoto Y, Saeki H, Yoshida N, Oki E,
Watanabe M, Oda Y, Bass AJ, Maehara Y, Baba
H (2016) Fibroblast growth factor receptor 2
expression, but not its genetic amplification, is
associated with tumor growth and worse sur-
vival in esophagogastric junction adenocarci-
noma. Oncotarget 7:19748–19761. https://
doi.org/10.18632/oncotarget.7782 - Walch A, Specht K, Braselmann H, Stein H,
Siewert JR, Hopt U, Hofler H, Werner M
(2004) Coamplification and coexpression of
GRB7 and ERBB2 is found in high grade
intraepithelial neoplasia and in invasive Barrett's
carcinoma. Int J Cancer 112:747–753.
https://doi.org/10.1002/ijc.20411 - Kumarasinghe MP, de Boer WB, Khor TS, Ooi
EM, Jene N, Jayasinghe S, Fox SB (2014)
HER2 status in gastric/gastro-esophageal
junctional cancers: should determination of
gene amplification by SISH use HER2 copy
number or HER2: CEP17 ratio? Pathology
46:184–187. https://doi.org/10.1097/
pat.0000000000000075 - Lange T, Nentwich MF, Luth M, Yekebas E,
Schumacher U (2011) Trastuzumab has anti-
metastatic and anti-angiogenic activity in a
spontaneous metastasis xenograft model of
esophageal adenocarcinoma. Cancer Lett
308(1):54–61. https://doi.org/10.1016/j.
canlet.2011.04.013- Safran H, Dipetrillo T, Akerman P, Ng T,
Evans D, Steinhoff M, Benton D, Purviance J,
Goldstein L, Tantravahi U, Kennedy T (2007)
Phase I/II study of trastuzumab, paclitaxel,
cisplatin and radiation for locally advanced,
HER2 overexpressing, esophageal adenocarci-
noma. Int J Radiat Oncol Biol Phys 67:405–
409. https://doi.org/10.1016/j.
ijrobp.2006.08.076 - Michalk M, Meinrath J, Kunstlinger H,
Koitzsch U, Drebber U, Merkelbach-Bruse S,
Bollschweiler E, Kloth M, Hartmann W,
Holscher A, Quaas A, Grimminger PP,
Odenthal M (2016) MDM2 gene amplification
in esophageal carcinoma. Oncol Rep 35:2223–
2227. https://doi.org/10.3892/
or.2016.4578 - Pal J, Bertheau R, Buon L, Qazi A, Batchu RB,
Bandyopadhyay S, Ali-Fehmi R, Beer DG,
Weaver DW, Shmookler Reis RJ, Goyal RK,
Huang Q, Munshi NC, Shammas MA (2011)
Genomic evolution in Barrett’s adenocarci-
noma cells: critical roles of elevated hsRAD51,
homologous recombination and Alu sequences
in the genome. Oncogene 30:3585–3598.
https://doi.org/10.1038/onc.2011.83 - Lockwood WW, Thu KL, Lin L, Pikor LA,
Chari R, Lam WL, Beer DG (2012) Integrative
genomics identified RFC3 as an amplified can-
didate oncogene in esophageal adenocarci-
noma. Clin Cancer Res 18:1936–1946.
https://doi.org/10.1158/1078-0432.
ccr-11-1431 - Akagi T, Ito T, Kato M, Jin Z, Cheng Y, Kan T,
Yamamoto G, Olaru A, Kawamata N, Boult J,
Soukiasian HJ, Miller CW, Ogawa S, Meltzer
SJ, Koeffler HP (2009) Chromosomal abnor-
malities and novel disease-related regions in
progression from Barrett’s esophagus to esoph-
ageal adenocarcinoma. Int J Cancer 125:2349–
2359. https://doi.org/10.1002/ijc.24620 - Pang C, LaLonde A, Godfrey TE, Que J, Sun
J, Wu TT, Zhou Z (2017) Bile salt receptor
TGR5 is highly expressed in esophageal adeno-
carcinoma and precancerous lesions with sig-
nificantly worse overall survival and gender
differences. Clin Exp Gastroenterol 10:29–37.
https://doi.org/10.2147/ceg.s117842 - Leicht DT, Kausar T, Wang Z, Ferrer-Torres
D, Wang TD, Thomas DG, Lin J, Chang AC,
Lin L, Beer DG (2014) TGM2: a cell surface
marker in esophageal adenocarcinomas.
J Thorac Oncol 9:872–881. https://doi.
org/10.1097/jto.0000000000000229
Katherine T. W. Lee et al.